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Abstract
Objective: A recent collaborative genome-wide association study replicated a large number of susceptibility loci and
identified novel loci. This increase in known multiple sclerosis (MS) risk genes raises questions about clinical applicability of
genotyping. In an empirical set we assessed the predictive power of typing multiple genes. Next, in a modelling study we
explored current and potential predictive performance of genetic MS risk models.
Materials and Methods: Genotype data on 6 MS risk genes in 591 MS patients and 600 controls were used to investigate
the predictive value of combining risk alleles. Next, the replicated and novel MS risk loci from the recent and largest
international genome-wide association study were used to construct genetic risk models simulating a population of 100,000
individuals. Finally, we assessed the required numbers, frequencies, and ORs of risk SNPs for higher discriminative accuracy
in the future.
Results: Individuals with 10 to 12 risk alleles had a significantly increased risk compared to individuals with the average
population risk for developing MS (OR 2.76 (95% CI 2.02–3.77)). In the simulation study we showed that the area under the
receiver operating characteristic curve (AUC) for a risk score based on the 6 SNPs was 0.64. The AUC increases to 0.66 using
the well replicated 24 SNPs and to 0.69 when including all replicated and novel SNPs (n=53) in the risk model. An additional
20 SNPs with allele frequency 0.30 and ORs 1.1 would be needed to increase the AUC to a slightly higher level of 0.70, and at
least 50 novel variants with allele frequency 0.30 and ORs 1.4 would be needed to obtain an AUC of 0.85.
Conclusion: Although new MS risk SNPs emerge rapidly, the discriminatory ability in a clinical setting will be limited.
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Introduction
Multiple sclerosis (MS) is caused by an interplay of multiple
genetic variants and environmental factors. The genetic influence
on MS is substantial, as evidenced by the 20-fold risk increase for
siblings of MS patients [1]. Part of the genetic risk is explained by
the MHC class II locus (HLA-DR15) [2]. In 2007 several novel risk
alleles for MS were identified by a genome-wide association
(GWA) study [3] and others confirmed the susceptibility loci by
meta-analyses and replication [4]. Since GWA the progress has
been rapid and more new risk loci have been identified and
confirmed [5,6,7,8,9]. A recent study in 9,722 cases and 17,376
controls identified 53 associated variants [9].
Given the gene-environmental and multi-genetic causes of MS,
these susceptibility variants mainly have weak effects and are likely
to contribute to a small increase in MS risk individually. It is
commonly agreed that testing single susceptibility genes is not
useful for prediction of MS risk, but the question remains whether
combining susceptibility loci in risk models could have an added
value on MS prediction in individuals. The predictive perfor-
mance of genetic risk models has been investigated for other
diseases in simulation studies [10,11]. These studies suggest that
the predictive value improves by combining multiple common
low-risk loci.
We investigated the extent to which MS risk can be predicted
using genetic risk models. First of all we tested in our empirical
data the predictive performance of 6 combined genotyped SNPs,
using risk scores compared to a prior chance of someone in our
population having MS. However whether genetic risk models will
potentially be used in clinical or public health practices depends on
the accuracy of the test to discriminate between individuals who
will develop MS and who will not. The discriminative accuracy is
generally expressed as the area under the receiver operating
characteristic curve (AUC). Therefore, secondly we tested the
potential performance of SNP genotyping in a simulation study by
adding risk genes into the model. For this, we constructed a risk
model based on 1) the 6 genotyped SNPs, 2) the 24 recently well
replicated genome-wide associated polymorphisms [9] and 3) the
53 replicated genome-wide associated polymorphisms including
the 29 newly identified polymorphisms [9]. Finally, we included
hypothetical variants in the risk model, in order to investigate the
future potential.
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Empirical study
Ethics Statement. This study was approved by the Ethics
Committee of the Erasmus University Medical Centre, METC
Erasmus MC Rotterdam. All participants were recruited in
Erasmus University Medical Centre and written informed
consent was obtained.
Study population. A total of 591 MS patients and 600
controls were included in this study. The MS patients were
recruited and ascertained as part of an ongoing nationwide study
on genetic susceptibility in MS and fulfilled McDonald criteria for
MS [12]. Details on ascertainment are given elsewhere [13].
Genotyping. The HLA-DRB rs3135388, EVI5 rs10735781,
CLEC16A rs64981169, CD58 rs12044852, IL7R rs6897932, and
IL2RA rs2104286 SNPs (table 1) were genotyped using the
MassARRAY system/Homogeneous MassExtend assay, following
the protocol provided by Sequenom. PCR extension primers were
designed using the Assay Design 3.0 program (Sequenom).
ThermoSequenase (Sequenom) was used for the base extension
reactions. Analysis and scoring were performed using the program
Typer 3.3 (Sequenom).
Risk score analysis. All statistical analyses on empirical data
were performed using SPSS version 15. Associations of individual
SNPs were investigated using logistic regression. We also applied
logistic regression analyses to investigate the combined predictive
value of the risk allele score based on all SNPs with and without
HLA-DRB (rs3135388) using the a priori probability of an individual
in our population developing MS as reference. As we tested a total
of 6 SNPs in our empirical study, the Bonferoni-corrected p-value
for significance was 0.008. The weighted risk allele score was
calculated by multiplying the number of risk alleles with the effect
size for each SNP obtained from the literature and summing this
up for each participant with complete genotype information, with
risk alleles being the alleles associated with increased risk of MS.
All analyses were adjusted for age and sex.
Simulation study
Modelling strategy. We used a modelling procedure that
has been developed and published previously [14], and which has
also been used by others [15]. Briefly, the procedure creates a
dataset with information on genotypes and disease status for a
population of 100,000 individuals. The dataset is constructed in
such a way that the odds ratios and frequencies of the genotypes
and the disease risk match the specified values, which are obtained
from the literature. Predicted MS risks are calculated using Bayes’
theorem, which states that the posterior odds of MS for each
individual is obtained by multiplying the prior odds by the
likelihood ratio (LR) of their genotype status on all polymorphisms.
The prior odds is calculated from the baseline population MS
risk (p) using the formula p/(1-p). Under the assumption of
independent genetic effects i.e., no linkage disequilibrium between
the genetic variants, the LR is obtained by multiplying the LRs of
all individual genotypes that are included in the risk model [16].
The LRs of the genotypes of each single genetic variant are
calculated from a genotype by disease status contingency table
[14]. This table is constructed from the frequency and ORs of the
genotypes and the population MS risk. The table can also be
constructed from allele frequencies and per allele ORs when
Hardy-Weinberg Equilibrium is assumed for the distribution of
the genotypes. The frequencies and ORs all are specified as
study parameters and varied between the simulation scenarios.
The posterior odds are converted into MS risks using the formula
odds/(1+odds).
Discriminative accuracy. The discriminative accuracy is
the extent to which the test results can discriminate between
individuals who will develop MS and those who will not [17]. The
AUC gives an assessment of the discriminative accuracy of a
prediction model and ranges from 0.5 (equal to tossing a coin) to
1.0 (perfect prediction). All simulations were repeated 100 times to
obtain robust estimates of the AUC. All results are presented as
averages of the repeated simulations. The obtained confidence
intervals were extremely small, often equal to the point estimate,
and therefore not presented in this paper. Analyses were
performed using R software (version 2.12.1) [18].
Simulation scenarios. Recently, a large GWA study was
presented as part of the collaboration between Wellcome Trust
Case Control Consortium 2 (WTCCC2) and the International
Multiple Sclerosis Genetics Consortium (IMSGC) [9]. Twenty-
three MS associated non- major histocompability complex (MHC)
loci were replicated in the primary GWAS involving 9,772 cases
and 7,296 controls with PGWAS,1*10
23. Table 2 provides the 23
replicated non-MHC SNPs with the combined ORs and p-value.
The risk allele frequency represents the allele frequency in control
population of UK, as being the largest sample. Table 2 also
includes the HLA-DRB1*15:01 MHC SNP, which have been
shown to significantly increase the risk for MS. These 24 risk SNPs
also include the 6 polymorphisms of our empirical data. The
collaboration also presented the identification of 29 novel
susceptibility loci as shown in table 3. This leads to a total of 53
risk SNPs.
Three different simulation scenarios were considered. In each
scenario genotypes and MS status were simulated for 100,000
individuals, assuming a lifetime MS risk of 0.1%. The first scenario
Table 1. Individual association of 6 genotyped SNPs in the empirical study.
Controls Cases
Gene Variant Risk Allele n genotyped RAF n genotyped RAF OR (95% CI) p-value
HLA-DRB rs3135388 T 599 0.14 588 0.28 2.53 (2.02–3.17) 8.14*10
216
EVI5 rs10735781 G 597 0.33 586 0.38 1.19 (1.01–1.42) 0.044
CLEC16A rs64981169 G 593 0.33 583 0.39 1.27 (1.07–1.51) 0.006
CD58 rs12044852 C 599 0.88 587 0.91 1.50 (1.14–1.97) 0.004
IL7R rs6897932 C 599 0.72 588 0.76 1.21 (1.00–1.46) 0.045
IL2RA rs2104286 A 595 0.73 581 0.76 1.14 (0.95–1.38) 0.157
RAF: risk allele frequency, OR: odds ratio, 95% CI: 95% confidence interval.
doi:10.1371/journal.pone.0026493.t001
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literature frequency. The second scenario assessed the increase in
AUC by adding additional risk alleles, starting with the 6
genotyped risk loci given the replicated ORs. We compared this
to the calculated AUC for validation of the simulation model.
Next, the AUC was calculated with the 24 replicated SNPs in the
recent Nature paper including the 6 genotyped SNPs. And finally,
the AUC was assessed on a risk model including the 29 novel
susceptibility loci on top of the replicated SNPs, leading to a total
of 53 SNPs. The third scenario investigated the magnitude of the
allele ORs of 1 to 100 polymorphisms that need to be added to the
risk model to increase the discriminative accuracy. Since there are
no models known in the literature for predicting MS risk we
pursued AUCs known to be used for other diseases in the literature
[19,20]. We investigated AUC thresholds of 0.70, 0.75, 0.80 and
0.85. The ORs were obtained for different frequencies of the risk
alleles.
Results
Empirical study
A total of 588 cases and 599 controls were successfully genotyped
for at least one polymorphism, while complete genotype informa-
tion on all polymorphisms was available for 564 cases and 581
controls. The mean age (SD) within the cases and controls was 45
(12) and 49 (17) years, respectively. The cases included 71% female
and the controls 55%. None of the polymorphisms deviated
significantly from Hardy Weinberg Equilibrium (lowest Hardy
Weinberg p-value=0.15 for IL2RA: rs2104286).
Table 1 shows the individual effects of each SNP on MS risk in
our genotyped population. Increased risk for MS was confirmed
for the minor alleles of EVI5, HLA-DRB and CLEC16A, and for the
major alleles of CD58 and IL7R. For IL2RA the association was not
statistically significant (OR 1.14, 95% CI 0.95–1.38). When
adjusting for multiple testing only HLA-DRB, CLEC16A and CD58
remained statistically significant.
Figure 1A shows the risk score when including all SNPs into the
model. The reference category is based on the a priori risk for
developing MS, which in our population was 49% (=564 cases
divided by 581 controls). Individuals with 0 to 5 risk alleles have a
significantly decreased risk for developing MS of 0.28 (95% CI
0.16–0.48) compared to the a priori risk for developing MS. On the
other end of the spectrum, individuals with 10 to 12 risk alleles
have a significantly increased risk of 2.76 (95% CI 2.02–3.77).
Figure 1B shows that, when excluding the variant with the
strongest risk effect (HLA-DRB) from the risk score, individuals
with 0 to 5 risk alleles have a decreased risk of 0.50 (95% CI 0.34–
0.73) and individuals with 8 to 10 risk alleles have an increased risk
Table 2. Summary of the 24 replicated multiple sclerosis associated risk loci.
Gene Variant Chromosome Risk allele RAF OR (95% CI) P-value
MMEL1 rs4648356 1 C 0.67 1.14 (1.12–1.16) 1.00*10
214
EVI5 rs11810217 1 A 0.25 1.15 (1.13–1.16) 5.80*10
215
CD58 rs1335532 1 A 0.87 1.22 (1.19–1.24) 3.20*10
216
RGS1 rs1323292 1 A 0.83 1.12 (1.10–1.14) 2.30*10
28
KIF21B rs7522462 1 G 0.70 1.11 (1.10–1.13) 1.90*10
29
CBLB rs2028597 3 G 0.91 1.13 (1.06–1.21) 2.10*10
24
TMEM39A rs2293370 3 G 0.80 1.13 (1.11–1.15) 2.70*10
29
IL12A rs2243123 3 G 0.29 1.08 (1.06–1.10) 7.20*10
26
IL7R rs6897932 5 G 0.73 1.11 (1.09–1.13) 1.70*10
28
PTGER4 rs4613763 5 G 0.13 1.20 (1.18–1.22) 2.50*10
216
HLA-DRB rs3135388 6 A 0.13 3.08 (not shown) ,1.0*10
2320
OLIG3 rs13192841 6 A 0.27 1.10 (1.09–1.12) 1.30*10
28
IL7 rs1520333 8 G 0.25 1.10 (1.08–1.11) 1.60*10
27
IL2RA rs3118470 10 G 0.32 1.12 (1.10–1.13) 3.20*10
211
ZMIZ1 rs1250550 10 A 0.35 1.10 (1.09–1.12) 6.30*10
29
CD6 rs650258 11 G 0.63 1.12 (1.10–1.13) 2.00*10
211
TNFRSF1A rs1800693 12 G 0.40 1.12 (1.11–1.14) 4.10*10
214
CYP27B1 rs12368653 12 A 0.47 1.10 (1.09–1.12) 1.70*10
29
MPHOSPH9 rs949143 12 G 0.28 1.08 (1.04–1.12) 1.50*10
24
CLEC16A rs7200786 16 A 0.46 1.15 (1.13–1.16) 8.50*10
217
IRF8 rs13333054 16 A 0.23 1.11 (1.10–1.13) 1.30*10
28
STAT3 rs9891119 17 C 0.36 1.11 (1.09–1.12) 1.80*10
210
TYK2 rs8112449 19 G 0.67 1.08 (1.07–1.10) 1.20*10
26
CD40 rs2425752 20 A 0.25 1.11 (1.10–1.13) 5.10*10
210
RAF: risk allele frequency, OR: odds ratio, 95% CI: 95% confidence interval.
OR and p-value represent the combined discovery and replication study results [9]. Risk allele frequency refers to allele frequency in control population of UK samples.
For CBLB is the discovery OR and p-value given.
Reprinted by permission from Macmillan Publishers Ltd: The International Multiple Sclerosis Genetics Consortium and The Wellcome Trust Case Control Consortium.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. 2011, Nature 476: 214–219.
doi:10.1371/journal.pone.0026493.t002
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developing MS.
Simulation study
Table 2 provides the 24 replicated SNPs from the recent Nature
paper [9] which have been shown to significantly increase the risk
for MS. These 24 risk SNPs include also the 6 polymorphisms of
our empirical data. Table 3 shows the 29 newly identified
polymorphisms in this Nature paper, leading to a total of 53 risk
SNPs.
First, we calculated that the AUC for the genotyped 6 SNPs
within the empirical data weighted on literature frequency was
0.64. Second, in the simulation study we assessed the AUC
increase by including additional risk alleles. The AUC for the
recently replicated ORs of the 6 SNP’s used in the empirical study
was 0.64. This showed to be the same as the calculated AUC from
the empirical study. Next, including the 24 known polymorphisms
in the model the AUC rised to 0.66, and slightly increased to 0.69
after including all 53 SNPs in the model (Figure 2). Finally, we
explored the possibilities in the future with new risk alleles to be
discovered. Table 4 shows the number of new risk genes with
specific allele frequencies in combination with different ORs that
would be needed in addition to the original 53 risk variants to
obtain AUCs of 0.70, 0.75, 0.80 and 0.85. For example to increase
the AUC just slightly to 0.70 we have to add to our model 20 new
variants, with a realistic OR of 1.1 and an allele frequency of 0.30.
However if we want to increase the AUC to 0.85 we have to add
50 new variants with an OR of 1.4 and an allele frequency of 0.30.
For more realistic ORs this would mean we would have to add
even more polymorphisms to the model.
Discussion
This study investigated the extent of MS prediction by genetic
risk models, using empirical and simulation data on the most
updated genetic information for MS. First, we showed that the
predictive performance of testing multiple genes can be enhanced
by using a combination of individual MS risk alleles. As expected,
Table 3. The 29 novel associated MS risk genes.
Gene Variant Chromosome Risk allele RAF OR OR (95% CI) P-value
VCAM1 rs11581062 1 G 0.29 1.12 (1.10–1.13) 2.50*10
210
No gene rs12466022 2 C 0.73 1.11 (1.10–1.13) 6.20*10
210
PLEK rs7595037 2 A 0.55 1.11 (1.10–1.12) 5.10*10
211
MERTK rs17174870 2 G 0.75 1.11 (1.09–1.13) 1.30*10
28
SP140 rs10201872 2 A 0.18 1.14 (1.12–1.16) 1.80*10
210
No gene rs669607 3 C 0.48 1.13 (1.12–1.15) 1.90*10
215
EOMES rs11129295 3 A 0.36 1.11 (1.09–1.12) 1.20*10
29
CD86 rs9282641 3 G 0.91 1.21 (1.18–1.24) 1.00*10
211
IL12B rs2546890 5 A 0.52 1.11 (1.10–1.13) 1.20*10
211
BACH2 rs12212193 6 G 0.47 1.09 (1.08–1.10) 3.80*10
28
THEMIS rs802734 6 A 0.69 1.10 (1.09–1.12) 5.50*10
29
MYB rs11154801 6 A 0.36 1.13 (1.11–1.15) 1.00*10
213
IL22RA2 rs17066096 6 G 0.24 1.14 (1.12–1.15) 6.00*10
213
TAGAP rs1738074 6 G 0.57 1.13 (1.12–1.15) 6.80*10
215
ZNF746 rs354033 7 G 0.74 1.11 (1.10–1.13) 4.70*10
29
MYC rs4410871 8 G 0.72 1.11 (1.09–1.12) 7.70*10
29
PVT1 rs2019960 8 G 0.23 1.12 (1.10–1.13) 5.20*10
29
HHEX rs7923837 10 G 0.62 1.10 (1.08–1.11) 4.90*10
29
CLECL1 rs10466829 12 A 0.50 1.09 (1.08–1.11) 1.40*10
28
ZFP36L1 rs4902647 14 G 0.53 1.11 (1.10–1.13) 9.30*10
212
BATF rs2300603 14 A 0.74 1.11 (1.09–1.12) 2.00*10
28
GALC rs2119704 14 C 0.92 1.22 (1.19–1.25) 2.20*10
210
MALT1 rs7238078 18 A 0.77 1.12 (1.10–1.14) 2.50*10
29
TNFSF14 rs1077667 19 G 0.79 1.16 (1.14–1.18) 9.40*10
214
MPV17L2 rs874628 19 A 0.72 1.11 (1.09–1.12) 1.30*10
28
DKKL1 rs2303759 19 C 0.25 1.11 (1.09–1.13) 5.20*10
29
CYP24A1 rs2248359 20 G 0.61 1.12 (1.10–1.13) 2.50*10
211
MAPK1 rs2283792 22 C 0.52 1.10 (1.08–1.11) 4.70*10
29
ODF3B rs140522 22 A 0.33 1.10 (1.09–1.12) 1.70*10
28
RAF: risk allele frequency, OR: odds ratio, 95% CI: 95% confidence interval.
OR and p-value represent the combined discovery and replication study results [9]. Risk allele frequency refers to allele frequency in control population of UK samples.
Reprinted by permission from Macmillan Publishers Ltd: The International Multiple Sclerosis Genetics Consortium and The Wellcome Trust Case Control Consortium.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. 2011, Nature 476: 214–219.
doi:10.1371/journal.pone.0026493.t003
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its high OR. However, even without HLA-DR there was an
increased, but small, risk for developing MS in people with 8 to 10
risk alleles. This underlines the current insight that multiple genes
exert a small effect on developing MS on top of the major
influence of HLA-DR [21,22].
Next, after validating the genetic risk models with simulated
genotype and MS status in a population of 100,000 individuals, we
estimated that the predictive value as reflected in AUCs would be
0.66 when all 24 well replicated GWA derived polymorphisms
were considered. Moreover, we showed that including the 29
novel risk genes increased the AUC only slightly to 0.69,
illustrating that even more than doubling the number of risk
SNPs does not increase the AUC sufficiently to make it useful in
clinical practice. The AUC of 0.69 is comparable to other risk
prediction models in MS [23,24,25]. In 2009, De Jager and
colleagues investigated the prediction of 16 MS susceptibility loci
using weighted genetic risk scores in three cohorts [23]. They
demonstrated a consistent discriminatory ability in three indepen-
dent samples (AUC varying 0.64–0.70). Gourraud and colleagues
also investigated the aggregation of genetic MS risk markers in
individuals by comparing multiple and single case families [24].
They showed that a greater genetic burden in siblings of MS
patients was associated with an increased MS risk (OR 2.1,
p=0.001). However, the AUC for genetic burden differences
between probands and siblings was only 0.57, indicating that the
available genetic data is not sufficient to achieve case-control
prediction of MS. They also used 16 MS susceptibility loci, partly
matching with those of De Jager et al.
Before interpreting the clinical relevance of our findings, a
methodological issue needs to be disclosed. We assumed that
genetic variants inherited independently and that the combined
effect of the genetic variants on disease risk followed a
multiplicative risk model of independent effects (i.e., no statistical
interaction terms were included in the model). Although so far no
studies have demonstrated gene-gene interactions with MS risk, it
is still possible that these will be discovered in future studies in
larger populations. However, gene-gene interactions only improve
the MS risk predictions if their effect sizes are substantially high
(e.g., OR.5). When interaction effects are smaller, their effects on
the predictive accuracy will be comparable with that of single gene
effects, because by definition their frequencies are lower.
With the current model including 53 variants, we are still not
able to differentiate with reasonable accuracy between individuals
who will develop MS and those who will not (AUC 0.69). This
makes our model not clinically useful. So the question is raised
how to improve MS prediction.
We demonstrated in the simulation study that in order to obtain
higher AUCs, a considerable number of additional common
genetic variants or stronger associated variants with high ORs
(table 4) need to be identified. The per-allele OR of the
polymorphisms identified in GWA studies ranges from 1.08 to
2.1. When future GWA studies will identify polymorphisms with
per-allele ORs around 1.1, the predictive ability of the genetic risk
model can theoretically be improved beyond that of the existing
models. Yet, even small improvements to 0.70 still require the
discovery of 20 new statistically significant variants. Despite the
increase it is still not clinically applicable. Because even in a disease
that is readily treatable and even preventable like coronary heart
disease (as presented in the Framingham Risk score) an AUC of
about 0.80 is used [26]. For MS there is still no cure or preventive
treatment available, and so a higher predictive accuracy is
desirable to prevent false positives. We have shown that to pursue
an AUC of 0.85, we have to include 50 new variants with ORs of
1.4 or a few common variants (minor allele frequency .30%) with
high ORs (table 4). This may prove to be difficult, because the
common genetic variants with high ORs may already have been
identified, which would imply that even higher numbers of
common genetic variants with relatively smaller ORs or many
exceedingly rare variants (minor allele frequency ,1%) with high
ORs, will be needed. This seems not feasible. To note, unlike
HLA-DR most of the genetic risk factors identified so far have only
a slight effect on susceptibility to MS (with ORs that range from
1.1 to 1.2) [23]. However, more high risk genetic MS risk variants
can be expected in near future [27]. With novel techniques such as
next generation sequencing we can expect new rare variants with
high ORs to be discovered [28]. This approach has already been
proven successful in rare Mendelian disorders and can potentially
Figure 1. Weighted Risk scores for the 6 genotyped SNPs. The
odds ratios for MS are shown according to the number of risk alleles
carried. The reference value is based on the a priori probability of
someone in the general population to carry MS risk alleles. A) Weighted
risk scores for the 6 genotyped SNPs including HLA-DRB. B) Weighted
risk scores for the 5 genotyped SNPs.
doi:10.1371/journal.pone.0026493.g001
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Risk allele
Frequency
Number of
extra genetic variants AUC 0.70 AUC 0.75 AUC 0.80 AUC 0.85
0.05 1 1.2 2.3 5.1 9.0
5 1.2 1.7 2.6 3.6
20 1.1 1.4 1.7 2.1
50 1.1 1.2 1.4 1.6
100 1.1 1.2 1.3 1.4
0.30 1 1.2 1.9 3.0 4.9
5 1.2 1.4 1.8 2.2
20 1.1 1.3 1.4 1.6
50 1.1 1.2 1.3 1.4
100 1.1 1.2 1.3 1.4
0.50 1 1.2 1.8 3.2 5.3
5 1.2 1.4 1.8 2.1
20 1.1 1.3 1.4 1.5
50 1.1 1.2 1.3 1.4
100 1.1 1.2 1.3 1.4
NOTE: Odds ratios are presented as mean of 20 simulations each.
AUC: area under the receiver operating characteristic curve.
doi:10.1371/journal.pone.0026493.t004
Figure 2. ROC curves for simulation models predicting MS. Four situations are depicted. Solid line (
____) represents ROC curve for
simulation model based on 6 genotyped SNPs (AUC 0.64). Dashed line (----) ROC curve for simulation model based on 24 well replicated SNPs (AUC
0.66). Dotted line (
……..) ROC curve for simulation model based on a total of 53 replicated and novel SNPs (AUC 0.69). Dash-dotted line (
_._. ) ROC
curve for simulation model based on 20 extra variants with an arbitrarily set allele frequency of 0.30 and OR 1.1 (AUC 0.70). Long- dashed line (
__ -
__)
ROC curve for simulation model based on 50 extra variants with an arbitrarily set allele frequency of 0.30 and OR 1.4 (AUC 0.85).
doi:10.1371/journal.pone.0026493.g002
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MS within families [29]. Also, this technique potentially allows us
to find the causal variants for MS which will most likely have
higher ORs than those found in GWA studies.
Another approach to improve MS prediction could be
combining genetic with nongenetic risk factors such as infection
with Epstein-Barr virus (EBV), smoking, and serum vitamin D
concentrations [30]. It is likely that risk prediction models
combined with nongenetic factors will perform better as ORs for
SNPs tend to be smaller than ORs based on nongenetic factors
(e.g. infectious mononucleosis [31]). De Jager and colleagues
showed an enhanced discriminatory ability of 16 susceptibility
genes by the inclusion of sex (AUC increasing from 0.70 to 0.74)
and smoking and immune response to EBV (AUC increasing from
0.64 to 0.68). Others have performed studies combining the effects
of HLA-DR and non-genetic factors like smoking and anti EBV
serum levels [32,33]. Also, integration of transcriptional, proteo-
mics, and clinical factors will probably improve the prediction
model and with that our understanding of MS genetics [34].
However, the added value of the SNPs might then be questioned.
For other diseases it has been shown that the AUC does not
improve a lot when adding SNPs to clinical risk factors. It should
be noted though, that in these studies only small numbers of SNPs
were added to the clinical risk factors.
Even if we can improve the prediction of MS in the future the
question remains what the clinical implications of such predictive
risk models would be. The discriminative accuracy that is required
in preventive or clinical care depends on the goal of testing, the
availability of (preventive) treatment, and the adverse effects of
false-positive and false-negative test results.
Although the early results from GWA studies have not yet been
used clinically, at least a partial goal of understanding the genetic
basis of MS is to investigate the use of these variants to predict
disease risk, so that environmental changes or therapeutic
interventions can be initiated before the inflammatory demyelin-
ating process progresses or even starts. Also, by better mapping the
genetic of MS, we hope to improve our understanding of the
pathofysiology of MS. This could help us finding better and new
therapeutic drugs. By combining family history with a quantitative
measure of genetic risk, a screening method might eventually be
implemented that could identify clinically silent evidence of disease
among first-degree relatives of MS patients, who have 20–50 times
higher risk of developing MS [35]. However, the absolute risk is
only 2–5% and therefore the models could be more useful in high
risk populations with individuals who have had clinically isolated
syndrome suggesting MS. These patients present with a neuro-
logical disability during their productive years of life and face the
possibility of a chronic disease. Thus, they yearn for more clarity
about their future. But also improving the risk prediction would
enable us to distinguish individuals at risk to start early treatment
for reducing the accumulation of neurological disability [36].
Given the possible clinical consequences of false-positivity
within these patients, the required prediction AUCs for the pre-
symptomatic diagnosis is considerably higher than an AUC
intended for clinically isolated syndrome. It has been suggested
that identified genetic variants have stronger effects in multiplex
families [37]. It is of note that the ORs assessed up to now in GWA
studies and validation studies are generally derived from datasets
on sporadic cases. In a multiplex family setting, with potential
stronger effects for individual risk variants, our estimates may
prove to be conservative.
In conclusion, our analyses show that prediction of MS risk
based on low susceptibility variants theoretically can improve
prediction of disease when more variants are being discovered.
However, the discriminatory ability in a clinical setting will be
limited.
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